Systemic lupus Erythematosus (SLE)

Introduction:

It is a multisystem autoimmune disease that can affect any part of the body affect young women. The disease occur 9:1 in women than in men. Characterized by presence of autoantibodies to nuclear antigens (DNA,RNA,Histonproteins), the immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage.

SLE most often affects the joints, skin, lungs, heart, blood vessels, liver, kidneys, and nervous system. SLE can be fatal causing death from cardiovascular disease.

- * <u>Etiology:</u> SLE develops by number of genetic and environmental factors.
- 1- SLE-disease develops with **inherited deficiencies** of classical pathway of complement system (C1q, C4 or C2) genes are located in chromosome 6.
- 2- hormones :- oestrogen may be regulates the severity of SLE.
- 3- Genetic factors: (In 30%), also associated with HLA-DR2 DR3.
- 4- Ultraviolet light (UV) and infections (Epstein-Barr virus),
- **5-** drugs : Sulfa drugs, such as: (trimethoprim-sulfamethoxazole) ,Penicillin :-amoxicillin; 6- defect in apoptosis and the clearance of damaged cells.

Types of lupus disease:-

1-**Systemic lupus erythematous** : It is marked by chronic inflammation, especially of the kidneys, joints, and skin. The cardiovascular and nervous systems can also be affected.

2-Lupus Limited to the Skin : The term refers to a specific form of lupus that is limited to the skin,

chronic cutaneous lupus erythematosus (CCLE) (also known as Discoid Lupus Erythematosus [DLE])

3-**Drug-Induced Lupus Erythematosus :** Certain drugs can cause lupus-like symptoms in people who do not have **SLE. It is temporary and** of the time that the medication is stopped.

4- Neonatal Lupus Erythematosus affect the babies of women with certain autoantibodies, Like (anti-Ro, anti-La, and anti-RNP.

5- Childhood Lupus Children affects in the same manner as adult lupus, organs affected, (kidneys)

Pathogenesis "

One manifestation of SLE is abnormalities in apoptosis,

- Autoimmune reactions directed against constituents of cell nucleus, DNA
- Antibody response related to B and T cell hyperactivity.

1- Immune responses against **endogenous nuclear antigens** are characteristic of SLE. **Autoantigens** released by apoptotic cells (programmed cell death) are presented by **dendritic cells** (**DC**) to T cells leading to their activation.

2- T cells Activate B cells to produce antibodies to these self-constituents

3- Immune complexes and complement activation pathways mediate effectors function and tissue injury by **inflammatory cytokines** such as **IFN** α and tumour necrosis factor (**TNF**).

Clinical Features : Lupus- can be further classified as:

1-Acute rashes-malar rash. 'butterfly'rash presents as an erythematous, pruritic or painful, in a malar distribution, commonly by exposure to sunlight.

2- Subacute cutaneous lupus erythematosus (SCLE). Patients with SCLE may present with psoriasiform skin lesions, and this is strongly associated with anti-Ro (SS-A) and anti-La (SS-B) antibodies. Patients have a high incidence of photosensitivity.

3-Chronic rashes : characterized by plaques covered by scale. They are oft en seen on the face, neck, and scalp, then heal, leaving depressed central scars, atrophy, and dyspigmentation



Main Criteria of SLE :

- 1- Malar Rash and Discoid rash
- 2- Photosensitivity
- **3-** Non-erosive arthritis
- 4- Renal disease
- 5- Antinuclear antibody
- 6- Antibody to ds-DNA/extractable nuclear Ag/anti-phospholipid Ab

Diagnosis of SLE: Blood test work and other tests can also help monitor the disease and treatment.

1-Hematologic disorders:

- -Hemolytic anemia
- -Leukopenia ,(Lymphopenia)
- -Thrombocytopenia
- Erythrocyte sedimentation rate **ESR** : and **C-Reactive Protein** (**CRP**): These tests looks for inflammation, which could indicate active lupus.

2-Kidney and liver functioning. Lupus can affect these organs.

3-Urinalysis. increased protein level or red blood cells in the urine,

4-Immunological tests:

1-Antiphospholipid antibodies (APL) (lupus anticoagulant [LA], IgG and IgM anticardiolipin [aCL] antibodies; and IgG and IgM anti-beta2-glycoprotein [GP] I)

2- decrease levels of C3 and C4 or CH50 complement levels

- 3- Anti nuclear antibodies (ANA)
- 4 -Anti-dsDNA highly specific for SLE seen in approximately 70 percent of patients with SLE.

B-Extractable nuclear antigens (ENA)

1-Anti-Sm (smith) antibodies are highly specific for SLE, but lack sensitivity (30%)

2- Anti-Ro/SSA and anti-La/SSB antibodies are present in 30 and 20 percent of patients with SLE, respectively; however, both antibodies are commonly associated with Sjögren's syndrome .

3-Anti-U1 RNP antibodies are observed in SLE and mixed connective tissue disease (MCTD) .

4-Anti-ribosomal P protein antibodies have a high specificity for SLE, with low sensitivity .

Management and Treatments :- No permanent cure for SLE: treatment relieves symptoms

1-NSAIDs (non-steroidal anti-inflammatory drugs) Aspirin ,ibuprofen for inflammation ,pain

2-Corticosteroids : Reduce inflammation Used after significant organ damage

4-DMARDs (disease-modifying antirhematic drugs) : rituximab Suppress B cell development,

